Abstract: Present invention provides improved compositions and methods of releasing cargo molecules to recipient cells. Described herein are engineered exosomes carrying neurotoxins and/or compounds, and releasing the neurotoxins to recipient cells by permeating the skin.

Abstract: Provided herein is a composition for brightening and/or whitening keratin materials, comprising in a hydrophilic phase: (i) at least one glycol with a log P being from ?0.5 to 4; (ii) at least one surfactant with a HLB value of 8-20 at the temperature of 25° C.; and (iii) at least one brightening and/or whitening ingredient selected from vitamin B3 and derivatives thereof, wherein the composition is oil-free. Also provided herein is to a non-therapeutic method for brightening and/or whitening keratin materials, comprising applying said composition to the keratin materials, and use of a combination of at least one glycol with a log P being from ?0.5 to 4 and at least one surfactant with HLB of 10-20 for improving penetration of a brightening and/or whitening ingredient selected from vitamin B3 and derivatives thereof into keratin materials.

Abstract: The present invention relates to a polymer carbon nitride, a specific crystal form of the polymer carbon nitride, and a cosmetic composition, an ultraviolet ray-blocking composition, and an external use skin preparation composition, which include the polymer carbon nitride. The polymer carbon nitride according to one aspect of the present invention and a crystal form produced by a specific preparation example thereof can absorb both UVA and UVB, and thus can effectively protect the skin from ultraviolet rays while also being non-toxic and thus suitable for living bodies and lacking photoactivity. Therefore, the polymer carbon nitride and the crystal form can be utilized in a cosmetic composition, an ultraviolet ray-blocking composition and an external use skin preparation composition, which are applied to the living body.

Abstract: A method for producing a coating film, including forming a coating film containing a deposit containing fibers on a surface of an object for forming a coating thereon by an electrostatic spray of a composition. The composition includes component (a) a polymer having a coating film forming ability, (b) one or more volatile substances selected from the group consisting of water, an alcohol and a ketone, and (c) an oil component being liquid at 25° C. and containing a component (c1) one or more selected from the group consisting of oil components having a surface tension at 25° C. of 25 mN/m or less and being liquid at 25° C.

Abstract: The present disclosure relates to a functional cosmetic composition using broccoli exosomes as an active ingredient and a functional cosmetic product containing the same. The broccoli exosomes have a lipid bilayer structure and are well absorbed into skin cells, and the absorbed broccoli exosomes remove reactive oxygen within skin cells and stimulate anti-oxidant signaling mechanisms, so they show anti-oxidant efficacy, and promote hyaluronic acid synthesis, and thus, they can be useful for preparation of functional cosmetics for skin aging prevention, skin whitening, wrinkle improvement and skin cell regeneration.

Abstract: A pet dental treat includes an outer shell constituting a dense, solid shell which keeps the dog occupied while the dog's teeth sink into a soft, chewy porous inner core, potentially coated on exposed surface(s) such as with a bio-active compound, to scrape tartar and remove plaque from the dog's teeth, including hard-to-reach teeth, thereby helping to maintain the oral health of the dog while also reducing bad breath. The pet dental treat has a cross-section visually resembling a tooth and includes a longitudinal slot defining an integral pocket having in-turned retaining elements at an entrance to the slot, with the pocket provided to selectively retain a functional, edible additive insert, such as a vitamin, medicinal item or the like insert, to be given to the pet, with the retaining elements preventing the edible insert from inadvertently falling out of the pocket.

Abstract: The present invention relates to an extract of bacterium of Sphingomonas genus, compositions comprising at least one bacterium of Sphingomonas genus or said extract, the uses thereof, as well as their implementations in cosmetic methods.

Abstract: Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.

Abstract: The present invention relates to topical ophthalmic composition of Apremilast. The said ophthalmic composition has been designed for better penetration and reach to the target site for ophthalmic applications, thereby giving a better efficacious formulation. The present invention also relates to method of relieving the symptoms of dry eye by enhancing the tear secretion, reducing inflammation and moisturising the surface of eye thereby reducing the friction or irritation, as is generally caused due to various dry eye disorders. The presently proposed compositions are also proposed to be useful as delivery vehicles for ophthalmic drugs, and as wetting or lubrication substitute for the contact lens.

Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Abstract: The present invention addresses the problem of providing an oral pouch product containing a novel oral composition to which a cool feeling (also referred to as sense of coolness, fresh taste, or the like) is imparted. The problem is solved by an oral pouch product formed from an oral composition containing nicotine, a sugar alcohol, and a cool feeling fragrance and a packaging material for packaging the oral composition. The weight ratio of the sugar alcohol to the cool fragrance is 10-1000.

Abstract: The present invention relates to a hydrogel material hydrogel material, comprising a first hydrogel comprising 0.15-21 wt-% of a functionalised triblock molecule having a formula (1) wherein n is 4-680 and m is 1-10, based on a total weight of the first hydrogel. The first hydrogel further comprises 0.85-3.3 wt-% of silica, based on the total weight of the first hydrogel, and 75-99 wt-% of an aqueous liquid, based on the total weight of the first hydrogel. The —Si—OH groups of the silica form a —Si—O—Si— bond with the —Si—(O)3— group of the functionalised triblock molecule of formula (1).

Abstract: Liquid, gel, and semi-solid compositions containing naloxone base, or isomers or derivatives thereof, with one or more non-aqueous solvents, and optional viscosity adjusting agents, are provided. Methods of treating an individual exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose including administering a liquid, gel, or semi-solid formulation containing a solution of naloxone base, or an isomer or a derivative thereof, in one or more non-aqueous solvents, are also provided.

Abstract: The present invention relates to oral hydrogel compositions, more particularly to thermosensitive gel compositions, which undergo a sol-gel transition in the oral cavity, and which optionally comprise therapeutic actives for sustained release.

Abstract: The present invention relates to formulations for the delivery of bioactive agents, and methods of preparing the formulations. More specifically, the present invention relates to a formulation for delivery of a bioactive agent comprising a hydrogel matrix that is the product of a reaction between hydroxypropyl methylcellulose (HPMC), acrylic acid (AAc) and N,N?-methylenebisacrylamide (MBA), and methods of preparing the formulations.

Abstract: Methods and compositions are provided for treating a patient having a bleeding disorder during or after a dental procedure to reduce bleeding or need for factor replacement therapy. Aqueous pharmaceutical compositions are provided comprising tranexamic acid, sodium carboxymethyl cellulose, Tween® 20, and menthol wherein the composition exhibits good long term stability, little to no discoloration over time, and reduced bitterness compared to a control solution of tranexamic acid and water.

Abstract: An emulsion including size-controlled droplets dispersed in a viscoelastic continuous phase including a polymer in solution in a solvent, wherein the viscoelastic continuous phase presents a ratio between the viscous modulus (G?) and the elastic modulus (G?) ranging from 0.2 to 10 and wherein the mean diameter of the droplets is proportional to the G?/G? ratio with 1.5 as exponent. Also, a process for the fabrication of size-controlled droplets in a viscoelastic continuous phase of an emulsion, and the use of the emulsion in applications requiring size-controlled droplets.

Abstract: Disclosed are compositions comprising a first liposome, comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, and at least one vasodilator; and a second liposome, comprising at least one lipid selected from the group consisting of saturated phospholipids, unsaturated phospholipids, mixed phospholipids, and cholesterol, at least one thiazolidinedione, and at least one compound having an affinity for at least one component of an atheroma. Also disclosed are methods for forming the compositions and methods of using the compositions to ameliorate atheroma.

Abstract: Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

Abstract: Ionizable cationic lipid compounds have an amine moiety from amino alcohols and a lipid moiety from a lipid synthesized via esterification. The ionizable cationic lipid compounds which comprise an amino alcohol mediated ionizable cationic lipid compound are useful for in vivo or in vitro delivery of one or more nucleic acid agents including DNA, siRNA, a microRNA, an mRNA, a RNAi, and a plasmid.

Abstract: A nanoparticle material, a process for obtaining the nanoparticle material, a product that includes the nanoparticle material, and methods of using the nanoparticle material. The nanoparticle material includes a resorbable nanoparticle that is functionalized with at least one compound.

Abstract: High(greater than 30%) and/or low(less than 10%) loaded multiple API powdered/nanoparticle were tabulated with increased flowability and physical properties. Properties include blend flowability and uniformity, bulk packing density, compactability, tensile strength, and dissolution. Blending is done through solventless dry mechanical coating of at least one minority API component defined as the API component with the least weight per volume surface coated with nano-sized powders in lesser amounts by wt % of the blend, and preferably less than 10% dry coated of the minority API. An excipient may be dry coated in the lesser amount wherein the excipient is a minority component. Both minority excipient and minority API may be dry coated. Using dry coating instead of dry granulation and/or wet granulation techniques in producing tablets saves manufacturing steps, costs, and produces higher quality tablets with surprisingly higher properties than expected for low flowability solid powdered ingredients.

Abstract: The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”).

Abstract: Fine dry particulate adenosine compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate adenosine composition, the adenosine active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate adenosine compositions of the invention, and methods of using the same.

Abstract: According to the invention, there is provided a pharmaceutically-acceptable composition which is preferably in the form of a spray-dried powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one pharmaceutically-active compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Abstract: An object of the present invention is to provide a medicine production method including a freeze-drying method that can reduce the residual solvent concentration in a wide substrate concentration range from low concentration to high concentration. The medicine production method according to the present invention includes the following steps: (1) providing a mixed solution containing water, an organic solvent, and a substance to be freeze-dried; and (2) subjecting the mixed solution to freeze-drying, wherein a weight percentage of the organic solvent based on a total weight of water and the organic solvent in the step (1) is 68% by weight or more and 99% by weight or less.

Abstract: The invention relates to stable prolonged release vitamin C formulation, which is free of any added stabilizer and exhibits prolonged release of the active. The formulation is comprised of at least one hydrophobic non-polymeric excipient and hydrophilic release controlling agent along with at least one excipient. The invention also relates to the process for preparation, wherein the active may be treated with hydrophobic release controlling agent, followed by aqueous granulation with hydrophilic release controlling agent. The granules can be converted into compressible dosage forms like tablets or filled in capsules or sachets. The formulation is stable and releases more than 85% of vitamin C over a period of 8 to 24 hours. The formulation can be suitably orally administered to the subjects in need thereof, for maintaining effective levels of vitamin C over prolonged time.

Abstract: The present invention is directed film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain a water-soluble polymer, an opacifying agent such as, calcium carbonate or starch, and isomalt. The film coating compositions can be in the form of a fully formulated dry blend or as an aqueous suspension which can be applied either directly to a substrate or after the substrate has been coated with a subcoat. Oral substrates such as tablets coated with the film coating compositions are also disclosed and have high opacity and overall excellent appearance.

Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.

Abstract: Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.

Abstract: Self-actuating articles including, for example, self-actuating needles and/or self-actuating biopsy punches, are generally provided. Advantageously, the self-actuating articles described herein may be useful as a general platform for delivery of a wide variety of pharmaceutical drugs that are typically delivered via injection directly into tissue due to degradation in the GI tract. The self-actuating articles described herein may also be used to deliver sensors and/or take biopsies without the need for an endoscopy. In some embodiments, the article comprises a spring (e.g., a coil spring, a beam, a material having particular mechanical recovery characteristics).

Abstract: A unique class of perfluorocarbon-free Dextran-based oxygen nanobubbles (DONBs) and formulations thereof. The critical components in the formulation are chosen among the U.S. Food, and Drug Administration's (FDA) approved compounds, which provide a biocompatible environment for incorporating pharmaceutical agents. Moreover, the nanobubbles are fabricated with simple sonication and homogenization method that easily fulfills the current good manufacturing practices (cGMP) requirements, which will promote scaleup production for commercial manufacturing. The formulated DONBs release oxygen over an extended period to keep the partial pressure of oxygen within the inner retina high and thus preserve retinal tissue from ischemia.

Abstract: The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) [a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group]. (I) (R1)(R2)C(OH)—(CH2)a—(O—CO)b—X. (A): (R11)(R12)—CH—(CO—O)c—(CH2)v-. (B):—(CH2)d-N(R3)(R4).

Abstract: Compositions and methods for the treatment and/or prevention and/or control of indications such as pain management, cancer, seizure disorders, and Parkinson's Disease using continuous drug delivery.

Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.

Abstract: The invention provides a novel curcuminoid composition and methods for its use and manufacture. The composition can be obtained from an extract from Curcuma longa rhizomes. The formulation of the composition provides enhanced bioavailability and stability of bisdemethoxycurcumin (BDMC) under gastrointestinal conditions. The composition of the invention finds use in methods of promoting health and wellness, and methods of treating neurological disorders and inflammatory disorders.

Abstract: Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and/or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.

Abstract: The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

Abstract: There is provided a method of treating onychomycosis of the nail, comprising topical application of a pharmaceutical composition comprising an antifungal allylamine compound and a non-aqueous solvent system, which method comprises a loading phase, during which the pharmaceutical composition is administered at least three times a week, followed by a maintenance phase, during which the pharmaceutical composition is administered no more than two times per week. There are further provided pharmaceutical compositions suitable for topical application to the nail comprising an antifungal allylamine compound, an organic acid component and a diol component, as defined herein, and their use in methods of treating onychomycosis.

Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Abstract: Storage stable aqueous ready-to-administer formulations comprising isoproterenol are presented with desirable stability characteristics. In preferred aspects, formulations are terminally sterilized and packaged in a suitable format, such as a polymeric bag with metalized overwrap and include a non-contact oxygen scavenger.

Abstract: The present invention relates to a pharmaceutical composition for improving cognitive ability or enhancing memory, and more specifically, to a health functional food for improving cognitive ability or enhancing memory, and a composite pharmaceutical composition for improving cognitive ability or enhancing memory, which are mixed compositions, respectively, for co-administration with other active materials exhibiting an effect of improving cognitive ability or enhancing memory. The pharmaceutical composition for improving cognitive ability or enhancing memory, according to the present invention, has been confirmed to exhibit an effect of significantly reducing cognitive impairment or memory loss caused by neurodegenerative brain diseases or inflammatory brain diseases such as autism, Alzheimer's disease, Parkinson's disease, peripheral neuropathy, amyotrophic lateral sclerosis, ischaemia, stroke and multiple sclerosis, etc.

Abstract: The present invention provides a use of valeric acid in preparation of a drug for preventing and treating diabetes and belongs to the technical field of diabetes treatment. The present invention provides a new use of the valeric acid and provides an effect of the valeric acid having a function of preventing and treating type 2 diabetes.

Abstract: Oral pharmaceutical compositions of gamma-hydroxybutyrate (GHB) suitable for concomitant administration with a dose of divalproex sodium (DVP) without materially altering the dosage amount of either drug are provided. Also provided are therapeutic uses of the compositions for the treatment of one or more symptoms of narcolepsy.

Abstract: The present invention relates to formulations in the form of a cream, an ointment, a liquid, or a gel and to the use of same to accelerate the healing of wounds and ulcers of mucous membranes and skin. The components of these formulations working together can effectively treat various surgical wounds, spontaneous ulcerations, post traumatic wounds, unhealed wounds, ulcers and bedsores. The formulations of the present invention can accelerate the reparation of wounds and ulcers by itself, reduce inflammation and swelling, relieve pain and itching, and accelerate the epithelialization processes also in cases that are not repairing despite of treatment with antiseptics and fibrinolytics.

Abstract: Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and/or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

Abstract: [Problem] To develop novel therapeutic agents for viral diseases such as coronavirus infections. [Solution] The present invention provides a therapeutic or prophylactic agent for viral diseases containing a compound with inhibitory activity against the function of Pin1 or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present disclosure describes methods of administering a pharmaceutical composition comprising a glutathione precursor and a thermoresponsive polymer via intranasal administration. In some embodiments, intranasal administration of the glutathione precursor can be used to treat a condition, for example, a central nervous system disorder.

Abstract: A method of treating Parkinson's Disease, Huntington's Disease and the like, diseases with abnormal dopamine-neurotransmission, using small molecules administered systemically that penetrate into the central nervous system to inhibit the rate-limiting step of dopamine synthesis in the central nervous system, the conversion of L-tyrosine to L-3, 4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase along with its cofactors tetrahydrobiopterin and iron (Fe+).

Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders.